Effects of APOE on cognitive aging in community-dwelling older adults.
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The apolipoprotein E (APOE) gene is an established risk factor for sporadic Alzheimer's disease, with elevated risk for ε4-carriers and reduced risk for ε2-carriers. However, it is unclear whether APOE modifies risk for cognitive decline in normal aging. The objective of this study was to determine whether ε2 and ε4 are associated with rates of normal cognitive aging, and whether associations of ε4 with cognitive decline are modified by sex, education or health behaviors (exercise, alcohol consumption, smoking). METHOD: A community-based sample of 1,393 older adults were genotyped for APOE and underwent cognitive assessment up to seven times over a maximum of period of 27 years. RESULTS: ε2-carriers showed slower executive function decline with age relative to ε3 homozygotes or ε4-carriers, whereas ε4-carriers demonstrated more rapid executive function and verbal fluency decline. Accelerated executive function decline was particularly pronounced in ε4-carriers with lower education. After excluding individuals with cognitive impairment, faster executive function decline was still apparent in ε4-carriers, and the effect of ε4 on episodic memory interacted with alcohol consumption, such that only ε4-carriers who did not drink showed more rapid memory decline than ε4 noncarriers. The influence of ε4 on cognitive aging did not differ by sex, nor was it modified by smoking or exercise. CONCLUSIONS: These findings indicate that the ε2 and ε4 alleles have differential effects on cognitive aging, and that negative effects of ε4 may be partly mitigated by behavioral choices. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease
Rovio, S., Kåreholt, I., Helkala, E.-L., Viitanen, M., Winblad, B., Tuomilehto, J., Soininen, H., Nissinen, A., & Kivipelto, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70198-8 · Cited by 1,054 · cited 2×
“, 2012), physical activity (Kivipelto et al., 2008; Rovio et al., 2005), alcohol consumption (Anttila et al.”
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 2×
“The apolipoprotein E (APOE) ε4 allele is one of the strongest genetic risk factors for sporadic Alzheimer’s disease, whereas the ε2 allele is protective against Alzheimer’s disease (Roses, 1996).”
Podewils, L. J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi092 · Cited by 675 · cited 2×
“, 2005), exercise (Niti, Yap, Kua, Tan, & Ng, 2008; Podewils et al., 2005; Schuit, Feskens, Launer, & Kromhout, 2001), alcohol consumption (Dufouil et al.”
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Apolipoprotein E and Cognitive Performance: A Meta-Analysis.
Small, B. J., Rosnick, C. B., Fratiglioni, L., & Bäckman, L. (2004) · Psychology and Aging · doi:10.1037/0882-7974.19.4.592 · Cited by 447
Effects of Moderate Alcohol Consumption on Cognitive Function in Women
Stampfer, M. J., Kang, J. H., Chen, J., Cherry, R., & Grodstein, F. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041152 · Cited by 396
Apolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347 · cited 1×
“ApoE genotype was determined as previously described (Siest et al., 1995).”
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Education and APOE-e4 in Longitudinal Cognitive Decline: MacArthur Studies of Successful Aging
Seeman, T. E., Huang, M.-H., Bretsky, P., Crimmins, E., Launer, L., & Guralnik, J. M. (2005) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/60.2.p74 · Cited by 88
Cited by
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
“Moreover, longitudinal studies show that APOE*ε2 carriers have lower rate of age-related decline in global cognition [12, 161], episodic memory [119], executive function [120], and verbal learning ability [162].”
BackgroundResultSeblova, D., Berggren, R., & Lövdén, M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101005 · Cited by 215
Dendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86
Granot‐Hershkovitz, E., Tarraf, W., Kurniansyah, N., Daviglus, M., Isasi, C. R., Kaplan, R., Lamar, M., Perreira, K. M., Wassertheil‐Smoller, S., Stickel, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12205 · Cited by 71
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Metadata
- Authors
- Reas, E. T., Laughlin, G. A., Bergstrom, J., Kritz-Silverstein, D., Barrett-Connor, E., & McEvoy, L. K.
- Venue
- Neuropsychology
- Published
- 2019-03
- Volume
- 33
- Issue
- 3
- Pages
- 406-416
- ISSN
- 0894-4105 (ISSN-L)
- 1931-1559
- OpenAlex
- W2911331420
- Cited by
- 83
- References
- 9
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.